Dual combination of actmera and hydroxy chloroquine to Combat

COVID-19 by using nanotechnology

Nael Kamel Eltewacy,, Amr Aly Resha, Rana khaled Mahmoud, Ahmed Abdelalim
Under the supervision: Eltewacy Arab Research Group
Email of Presenting author: rana.aly.student@pua.edu.eg

Abstract
SARS-CoV-2, which originally rose out of Wu-
han, China, has unleashed devastation in China
as well as the entire world. the day has called
scientists from one side of the planet to the other
to have their influence in driving this SARS-
CoV-2 pandemic to an end.

This is what we have seen from the rapid release

and spread of global vaccines in the world, as
well as the adoption of some medicines from the
World Health Organization.
The mini-studies shed light on the viable actions
that can be taken to reduce the spread of
COVID-19.
Such as the use of Tocilizumab, which is used in
genetically engineered monoclonal antibodies
humanized from a mouse antihuman IL-6R an-
tibody.
Tocilizumab perceives the IL-6 restricting site
of the human IL-6R and restrains IL-6 motion-
ing through an aggressive barricade of the IL-6
restricting site, to keep away from some inci-
dental effects and to further develop methodolo-
gies for focusing on and In certain cases copy-
ing these cell types to improve therapeutic out-
comes modern nanotechnology has used by the
emergence of Respiratory delivery of favipi-
ravir-tocilizumab combination through mucoad-
hesive protein-lipidic nanovesicles.
The consolidation of medical science with nano-
technology may fix the current issue by investi-
gating the combination advantages. In this com-
position, we hypothetically proposed the
Dual- combination. Cutting edge and expected
use of nanocarriers, for example, nano-
spheres/nanocapsules, nanocrystals, liposomes,
strong lipid nanoparticles/nano-organized lipid
transporters, dendrimers, and nanosponges for
biomimicry as well as targeted delivery of bio-
active to cells are accounted for thus and their
possible use in the fighting of COVID-19.
Figure 1: Tocilizumab (TCZ) is a recombinant human-
ized anti-interleukin-6 receptor (IL-6R) monoclonal anti-
body in addition to Chloroquine which inhibits the pro-
duction of IL-6. By duo-combination in a Nano-form, the
efficacy will increase as well as side-effects will decrease.
Physicochemical properties, such as, hydro-
philicity, molecule shape, surface charge, com-
position , concenteration, the utilization of vari-
ous target specific ligands on the carriers, and
the effect on carrier efficacy and specificity are
likewise examined.
The advantages of merged application of detec-
tion and therapeutics of nanomaterials have
been widely used in malignancy research be-
fore; however, their effictivness is unknown in
elimination infectious diseases resulted from
viruses, bacteria, and fungi. There exist extraor-
dinary potential in managing new and arising
disease like COVID-19 with the assistance of
nanomaterials.
Based on studies that indicated hydroxychloro-
quine and possession of the same Tocilizumab
mechanics, this research examined the na-
noscales of both compounds and overcome their
individual problems. The respiratory delivery
system according to a combination between two
drugs will be very effective in fully supporting
immunity, improving targeting, increasing im-
pact, and reducing side effects in the future.